Oncolytic viruses represent one of the most innovative approaches in cancer immunotherapy. These viruses are designed or selected to selectively infect and kill cancer cells while sparing normal tissue. But their impact goes beyond direct cell killing — oncolytic viruses can also stimulate the immune system to recognize and attack tumors, creating a dual mechanism of action. As research advances and approvals expand, the oncolytic virus cancer immunotherapy market is growing.

The oncolytic virus cancer immunotherapy market includes engineered viruses, clinical-stage products, and related technologies used to treat various cancers. Growth is driven by advances in genetic engineering, immunotherapy research, and the need for new treatment options in hard-to-treat cancers.

What Are Oncolytic Viruses?

Oncolytic viruses are viruses that preferentially infect and destroy cancer cells. They can be naturally tumor-selective or genetically engineered for enhanced selectivity and potency. Some also carry therapeutic genes that enhance anti-tumor effects.

How They Work

• Direct tumor cell killing: viruses replicate in cancer cells and cause cell death

• Immune activation: cell death releases tumor antigens that stimulate immune responses

• Microenvironment modulation: can turn "cold" tumors "hot" for immunotherapy

• Combination potential: often combined with checkpoint inhibitors

People Also Ask

What is oncolytic virus therapy?
It's a cancer treatment that uses viruses to selectively infect and kill cancer cells while stimulating an immune response against the tumor.

Are oncolytic viruses approved for cancer treatment?
Yes, some oncolytic viruses are approved in certain regions for specific cancers, and many more are in clinical trials.

The Dual Mechanism Advantage

The ability to both directly kill cancer cells and stimulate immune responses makes oncolytic viruses attractive for combination therapy. They may help overcome resistance to checkpoint inhibitors by turning immunologically "cold" tumors into "hot" ones that respond better to immunotherapy.

Tags: #OncolyticViruses #CancerImmunotherapy #Virotherapy #TumorImmunology #CancerTreatment #ImmunoOncology #Oncology